Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liposomes Clear all
Completed Phase 1 Interventional

Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

NCT00389428
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00004112
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular

NCT02242201
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
PNB Bupivacaine, PAI Ropivacaine, PAI liposomal bupivacaine, Epinephrine, Ketorolac
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 25, 2026, 9:29 AM EDT
Terminated Phase 4 Interventional Results available

Exparel vs. Standard Bupivicaine for Abdominoplasty

NCT01853176
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal Injection Bupivacaine (Exparel), Standard bupivicaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 25, 2026, 9:29 AM EDT
Enrolling by invitation Phase 4 Interventional

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

NCT06995352
View directory record Official record
Conditions
Moderate-to-severely Painful Ankle Surgery
Interventions
Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

NCT02210247
View directory record Official record
Conditions
Healthy Volunteers
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 25, 2026, 9:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 25, 2026, 9:29 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Efficacy of Single Injection Femoral Nerve Block With Liposomal Bupivacaine for Total Knee Arthroplasty

NCT01977339
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Liposome Bupivacaine, Bupivacaine
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 25, 2026, 9:29 AM EDT
Terminated Phase 4 Interventional Results available

The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics

NCT03290196
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
EXPAREL 1.3 % in 20 ML Injection
Drug
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years to 72 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

NCT00379340
View directory record Official record
Conditions
Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
199
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 25, 2026, 9:29 AM EDT
Withdrawn Phase 1Phase 2 Interventional

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

NCT04109690
View directory record Official record
Conditions
MDS
Interventions
CPX-351
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 78 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 25, 2026, 9:29 AM EDT
Terminated Phase 1 Interventional

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

NCT00515788
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
DepoCyt, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NCT02431559
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Durvalumab, Pegylated Liposomal Doxorubicin, Motolimod
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • New York, New York • Hilliard, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures

NCT02875288
View directory record Official record
Conditions
Pain, Postoperative
Interventions
liposomal bupivicaine
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 9:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Guided Posterior Quadratus Lumborum Block for Postoperative Analgesia in Gynecologic Surgery

NCT04549090
View directory record Official record
Conditions
Post-operative Pain, Gynecologic Surgery, Regional Anesthesia
Interventions
QL (quadratus lumborum) block administration
Drug
Lead sponsor
Pedram Bral
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

NCT04269213
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Omaha, Nebraska • Buffalo, New York • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 25, 2026, 9:29 AM EDT
Recruiting Phase 1 Interventional

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

NCT07492316
View directory record Official record
Conditions
Recurrent Medulloblastoma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 39 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 1 Interventional

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

NCT02022644
View directory record Official record
Conditions
High Grade Glioma
Interventions
nanoliposomal irinotecan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 25, 2026, 9:29 AM EDT
Not listed Phase 3 Interventional

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

NCT00002811
View directory record Official record
Conditions
Precancerous Condition
Interventions
liposomal T4N5 lotion
Drug
Lead sponsor
Applied Genetics
Industry
Eligibility
2 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
7
States / cities
Miami Beach, Florida • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies

NCT00038207
View directory record Official record
Conditions
Soft Tissue Sarcoma, Lymphoma, Leukemia, Wilms' Tumor, Osteosarcoma
Interventions
Liposomal Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

NCT02517905
View directory record Official record
Conditions
Dental Pain
Interventions
Bupivacaine liposome, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 25, 2026, 9:29 AM EDT
Recruiting Phase 2 Interventional

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

NCT06411795
View directory record Official record
Conditions
Duodenal Neoplasm, Pancreatic Neoplasm
Interventions
Bupivacaine, Hydromorphone, Iopamidol, Liposomal Bupivacaine, Medical Chart Review, Questionnaire Administration, Thoracic Epidural Analgesia, Ultrasound Imaging, X-Ray Imaging
Drug · Other · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 25, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

NCT04504812
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Duloxetine, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices
Drug · Combination Product · Procedure + 2 more
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 25, 2026, 9:29 AM EDT